A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : neo

Search Conditions:
Search Keyword : neo
Search Method : Exact match.
Research Area:

Results:  
Hit abbr.: 2 kinds.
(Click one to see its hit entries.)

(Appearance freq, Descending)
Abbreviation: neo
Appearance Frequency: 387 time(s)
Long forms: 56

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
neomycin phosphotransferase
(118 times)
Molecular Biology
(24 times)
CAT (8 times)
ES (5 times)
GFP (5 times)
1982 Nucleotide sequence and exact localization of the neomycin phosphotransferase gene from transposon Tn5.
neomycin
(78 times)
Molecular Biology
(13 times)
AMP (7 times)
GEN (7 times)
CHL (4 times)
1974 Transduction and plasmid deoxyribonucleic acid analysis in a multiply antibiotic-resistant strain of Staphylococcus epidermidis.
neomycin resistance gene
(70 times)
Molecular Biology
(10 times)
GFP (5 times)
TK (5 times)
PCR (4 times)
1984 Plasmidial maintenance in rodent fibroblasts of a BPV1-pBR322 shuttle vector without immediately apparent oncogenic transformation of the recipient cells.
neomycin resistance
(49 times)
Molecular Biology
(14 times)
TK (7 times)
GFP (4 times)
CHO (3 times)
1983 Retrovirus transduction: generation of infectious retroviruses expressing dominant and selectable genes is associated with in vivo recombination and deletion events.
neomycin gene
(6 times)
Virology
(2 times)
3'UTR (1 time)
CAT (1 time)
ES (1 time)
1991 Introduction of a subtle mutation into the Hox-2.6 locus in embryonic stem cells.
neocuproine
(5 times)
Fluorescence
(2 times)
phen (4 times)
bipy (2 times)
CHME (2 times)
1993 Oxidative stress by menadione affects cellular copper and iron homeostasis.
neomycin-resistance-encoding gene
(4 times)
Molecular Biology
(4 times)
DHFR (1 time)
ES (1 time)
FVII (1 time)
1992 A high-level expression vector for human cells.
neoantigen, fg-D
(3 times)
Medicine
(1 time)
--- 1973 Immunobiology of fibrinogen. Emergence of neoantigenic expressions during physiologic cleavage in vitro and in vivo.
neoamphimedine
(2 times)
Molecular Biology
(1 time)
ChIP (1 time)
Co-IP (1 time)
CRCs (1 time)
2014 An improved high yield total synthesis and cytotoxicity study of the marine alkaloid neoamphimedine: an ATP-competitive inhibitor of topoisomerase IIalpha and potent anticancer agent.
10  neochrome
(2 times)
Biochemistry
(2 times)
phot (2 times)
FMN (1 time)
LOV (1 time)
2007 Chloroplast photorelocation movement mediated by phototropin family proteins in green plants.
11  neomycin gene cluster
(2 times)
Biochemistry
(2 times)
btr (2 times)
DOS (1 time)
gnt (1 time)
2005 The neomycin biosynthetic gene cluster of Streptomyces fradiae NCIMB 8233: characterisation of an aminotransferase involved in the formation of 2-deoxystreptamine.
12  neomycin resistance cassette
(2 times)
Biology
(1 time)
HDA (1 time)
L9'S (1 time)
WT (1 time)
2006 Enhanced expression of hypersensitive alpha4* nAChR in adult mice increases the loss of midbrain dopaminergic neurons.
13  neomycin resistance marker gene
(2 times)
Science
(1 time)
--- 1993 Cloning and sequencing of the ura3 locus of the methylotrophic yeast Hansenula polymorpha and its use for the generation of a deletion by gene replacement.
14  unitary expression of fg-D
(2 times)
Medicine
(1 time)
--- 1973 Immunobiology of fibrinogen. Emergence of neoantigenic expressions during physiologic cleavage in vitro and in vivo.
15  1-methyl-2-nitroimidazol-5-ylmethyl carbamate of phenylenediamine mustard was metabolized rapidly by EMT6-NTR
(1 time)
Chemistry
(1 time)
GDEPT (1 time)
NTR (1 time)
2003 Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
16  necessary to decide on either
(1 time)
Diagnostic Imaging
(1 time)
HNC (1 time)
MRI (1 time)
2007 Lymph node staging.
17  necessary to proceed to future studies in which
(1 time)
Neoplasms
(1 time)
CMSs (1 time)
2020 Improving clinical management of colon cancer through CONNECTION, a nation-wide colon cancer registry and stratification effort (CONNECTION II trial): rationale and protocol of a single arm intervention study.
18  negative impacts of racialisation in a
(1 time)
Health Services
(1 time)
--- 2016 The significance of socially-assigned ethnicity for self-identified Maori accessing and engaging with primary healthcare in New Zealand.
19  negative patients who did not receive
(1 time)
Neoplasms
(1 time)
EMT (1 time)
ER (1 time)
HER2 (1 time)
2018 The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome.
20  neo vector control
(1 time)
Biochemistry
(1 time)
ROS (1 time)
WT (1 time)
2008 Late ROS accumulation and radiosensitivity in SOD1-overexpressing human glioma cells.
21  neoantigen of fibrinogen, fg-D
(1 time)
Science
(1 time)
--- 1974 The number of D and E regions in the fibrinogen molecule.
22  neomycin insertion
(1 time)
Genetics, Medical
(1 time)
NF1 (1 time)
2016 NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.
23  neomycin phosphotransferase-encoding gene
(1 time)
Molecular Biology
(1 time)
ori (1 time)
1992 A versatile shuttle cosmid vector for use in Escherichia coli and actinomycetes.
24  neomycin resistance aminoglycoside phosphotransferase
(1 time)
Neoplasms
(1 time)
CAT (1 time)
ER (1 time)
1992 Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor.
25  neomycin resistance expression cassette
(1 time)
Virology
(1 time)
6-TG (1 time)
AAV (1 time)
AP (1 time)
2003 Chromosomal integration and homologous gene targeting by replication-incompetent vectors based on the autonomous parvovirus minute virus of mice.
26  neopentane
(1 time)
Chemistry
(1 time)
iso (1 time)
2009 Neutron scattering and molecular dynamics evidence for levitation effect in nanopores.
27  neoplasm, rare cysts
(1 time)
Gastroenterology
(1 time)
IPMN (1 time)
MCN (1 time)
MPD (1 time)
2018 European evidence-based guidelines on pancreatic cystic neoplasms.
28  neosynephrine
(1 time)
General Surgery
(1 time)
ACEIs (1 time)
CPB (1 time)
2012 High flow and high dose neosynephrine are effective to maintain perfusion pressure for the patient with preoperative angiotensin converting enzyme inhibitor during cardiopulmonary bypass.
29  NEPA efficacy and tolerability during
(1 time)
Palliative Care
(1 time)
CINV (1 time)
2020 NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin.
30  Netherlands improved over the last two decades; more patients received
(1 time)
Gynecology
(1 time)
EOC (1 time)
RER (1 time)
2012 Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands.
31  Neupogen(), in breast cancer patients receiving
(1 time)
Neoplasms
(1 time)
ANC (1 time)
DSN (1 time)
FN (1 time)
2015 Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
32  neural cells in MAO A
(1 time)
Neurology
(1 time)
ES (1 time)
MAO (1 time)
WT (1 time)
2011 Monoamine oxidase A regulates neural differentiation of murine embryonic stem cells.
33  neurosurgery, and pathology, or an interdisciplinary treatment regimen including
(1 time)
Otolaryngology
(1 time)
--- 2019 [Importance of interdisciplinary collaboration for optimal treatment of orbital tumors].
34  new generation
(1 time)
Medicine
(1 time)
--- 2013 WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.
35  new or worsened UI is common after
(1 time)
Neoplasms
(1 time)
BMI (1 time)
QOL (1 time)
UI (1 time)
2020 Serial Assessment of Urinary Incontinence in Breast Cancer Survivors Undergoing (Neo)Adjuvant Therapy.
36  New Zealand, and China did not receive
(1 time)
Neoplasms
(1 time)
EBC (1 time)
MBC (1 time)
2018 The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.
37  newly diagnosed stage II/III breast cancer eligible to receive
(1 time)
Hematology
(1 time)
ANC (1 time)
SD (1 time)
2019 Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
38  newly formed
(1 time)
Molecular Biology
(1 time)
--- 2016 The challenge of evolving stable polyploidy: could an increase in "crossover interference distance" play a central role?
39  node dissection
(1 time)
Breast Neoplasms
(1 time)
WAI (1 time)
2019 Self-reported work ability in breast cancer survivors; a prospective cohort study in the Netherlands.
40  node dissection, radiotherapy
(1 time)
Medicine
(1 time)
--- 2019 A conditional model predicting the 10-year annual extra mortality risk compared to the general population: a large population-based study in Dutch breast cancer patients.
41  node positive disease following
(1 time)
General Surgery
(1 time)
ALND (1 time)
ARM (1 time)
NAC (1 time)
2015 Axillary reverse mapping (ARM) in clinically node positive breast cancer patients.
42  node-negative disease who did not receive any
(1 time)
Neoplasms
(1 time)
EMT (1 time)
mtDNA (1 time)
2016 Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis.
43  non-Basal-like within TNBC might predict survival following
(1 time)
Breast Neoplasms
(1 time)
TNBC (1 time)
2015 Clinical implications of the intrinsic molecular subtypes of breast cancer.
44  Non-Mendelian inheritance of a selectable marker
(1 time)
Botany
(1 time)
DSB (1 time)
2018 Experimental reconstruction of double-stranded break repair-mediated plastid DNA insertion into the tobacco nucleus.
45  Non-metastatic breast cancer women undergoing
(1 time)
Breast Neoplasms
(1 time)
CIA (1 time)
CT (1 time)
HP (1 time)
2020 "Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia".
46  non-metastatic disease who received taxane-containing
(1 time)
Neoplasms
(1 time)
IBC (1 time)
OS (1 time)
PD-L1 (1 time)
2019 Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
47  non-small cell lung cancers
(1 time)
Pulmonary Medicine
(1 time)
--- 2008 [Early-stage NSCLC. Resectable non-small cell lung cancers: (neo) adjuvant chemotherapy].
48  nonadministered animals or animals transplanted with control
(1 time)
Drug Therapy
(1 time)
DHFR (1 time)
LTR (1 time)
Mtxr-DHFR (1 time)
1993 Selective expression of methotrexate-resistant dihydrofolate reductase (DHFR) activity in mice transduced with DHFR retrovirus and administered methotrexate.
49  normal in Ipl nulls with the Ipl
(1 time)
Science
(1 time)
PH (1 time)
2002 Placental overgrowth in mice lacking the imprinted gene Ipl.
50  normal lectin histochemistry in accompany with biotinylated
(1 time)
Molecular Biology
(1 time)
--- 2008 Mammalian lectin as tool in glycochemistry and histochemistry with relevance for diagnostic procedure.
51  normally expressed in prx-1
(1 time)
Biology
(1 time)
--- 1999 prx-1 functions cooperatively with another paired-related homeobox gene, prx-2, to maintain cell fates within the craniofacial mesenchyme.
52  novel
(1 time)
Gastroenterology
(1 time)
--- 2014 Adjuvant therapy for gastric cancer: current and future directions.
53  nuclear presence of endogenous carbohydrate-binding proteins by application of labelled
(1 time)
Neurology
(1 time)
--- 1988 Endogenous carbohydrate-binding proteins in oligodendrogliomas. A histochemical study.
54  nuclear promoter-driven kanamycin resistance gene
(1 time)
Botany
(1 time)
--- 2011 Introducing an RNA editing requirement into a plastid-localised transgene reduces but does not eliminate functional gene transfer to the nucleus.
55  P25-hIGF-ie-neo containing a neomycin-resistance gene
(1 time)
Biotechnology
(1 time)
GFP (1 time)
hIGF-I (1 time)
2011 Expression of the hIGF-I gene driven by the Fhx/P25 promoter in the silk glands of germline silkworm and transformed BmN cells.
56  pEF321-neo
(1 time)
Neurology
(1 time)
CaM kinase II (1 time)
1993 Overexpression of Ca2+/calmodulin-dependent protein kinase II in Neuro2a and NG108-15 neuroblastoma cell lines promotes neurite outgrowth and growth cone motility.